June 19, 2020

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296
Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Indian regulator approves Favipiravir for the treatment of mild to moderate COVID-19 in India

We would like to inform you that Glenmark Pharmaceuticals has just received the manufacturing and marketing approval from India’s drug regulator to launch the oral antiviral drug Favipiravir (Fabiflu®) for the treatment of mild to moderate COVID-19 patients in India. This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak. It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

We will provide more details shortly.

This is for your information and record please.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

HARISH
VINAYAK KUBER
Harish Kuber
Company Secretary & Compliance Office

* Fabiflu® is a prescription product.

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
Registered office: B/2, Mahalakshmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com